Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

St. David's South Austin enrolled the first patient in a global lymphoma therapy study using a next-generation CAR T approach ...

A retrospective study evaluates the effectiveness of CD19 CAR T-cell therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with extramedullary or CNS disease.

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

PeproMene Bio, Inc. announced today that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell ...

This Collection provides updated research from the Immune cell engineering for cancer therapy 2024 Collection. Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung ...

Soficabtagene geleucel (WU-CART-007) received FDA Breakthrough Therapy Designation for treating relapsed or refractory T-cell leukemia and lymphoma. The CRISPR-engineered treatment achieved a 91% ...

In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...

WORCESTER, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ...